Adamis Pharmaceuticals Corporation (ADMP): Price and Financial Metrics


Adamis Pharmaceuticals Corporation (ADMP)

Today's Latest Price: $1.01 USD

0.13 (-11.41%)

Updated Aug 12 2:13pm

Add ADMP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ADMP Stock Summary

  • For ADMP, its debt to operating expenses ratio is greater than that reported by only 12.7% of US equities we're observing.
  • Revenue growth over the past 12 months for Adamis Pharmaceuticals Corp comes in at 30.08%, a number that bests 84.71% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ADMP comes in at -22.18% -- higher than that of merely 16.22% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Adamis Pharmaceuticals Corp, a group of peers worth examining would be YELP, SMAR, XXII, FFIV, and MITK.
  • Visit ADMP's SEC page to see the company's official filings. To visit the company's web site, go to www.adamispharmaceuticals.com.
ADMP Daily Price Range
ADMP 52-Week Price Range

ADMP Stock Price Chart Technical Analysis Charts


ADMP Price/Volume Stats

Current price $1.01 52-week high $1.51
Prev. close $1.14 52-week low $0.27
Day low $0.88 Volume 9,529,093
Day high $1.11 Avg. volume 2,866,827
50-day MA $0.79 Dividend yield N/A
200-day MA $0.64 Market Cap 74.65M

Adamis Pharmaceuticals Corporation (ADMP) Company Bio


Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. The company is based in San Diego, California.





ADMP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMP Latest Social Stream


Loading social stream, please wait...

View Full ADMP Social Stream

Latest ADMP News From Around the Web

Below are the latest news stories about Adamis Pharmaceuticals Corp that investors may wish to consider to help them evaluate ADMP as an investment opportunity.

Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock?

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

Yahoo | July 23, 2020

Adamis Pharmaceuticals Provides Update on SYMJEPI Products

Adamis Pharmaceuticals Corporation (ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting Adamis’ SYMJEPI ® (epinephrine) Injection 0.3mg and SYMJEPI ® (epinephrine) Injection 0.15mg products through its field sales force. As contemplated by the previously announced termination agreement between Adamis and Sandoz Inc., and the previously announced exclusive distribution and commercialization agreement between Adamis and USWM, USWM has been actively promoting SYMJEPI while preparing to launch through its field sales force.

Yahoo | July 1, 2020

Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose

Naloxone is an opioid antagonist used to treat narcotic overdoses. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl. Rapid resuscitation of an opioid overdose with naloxone, an opioid antagonist, is critical as opioid induced toxicity results in rapid death, i.e., delaying adequate resuscitation can result in death.

Yahoo | June 18, 2020

Adamis in-licenses drug for potential treatment of COVID-19

Adamis Pharmaceuticals ([[ADMP]] +7.7%) inks an an agreement with Matrix Biomed for global rights to Tempol for the treatment of respiratory diseases, including COVID-19, in addition to a dermatology indication: preventing radiation dermatitis in patients undergoing treatment for cancer.Under the terms of the deal, Adamis paid Matrix $250K upfront plus...

Seeking Alpha | June 15, 2020

Why Adamis Pharma's Stock Is Trading Higher Today

Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of coronavirus and respiratory disease. Adamis Pharmaceuticals is … Full story available on Benzinga.com

Benzinga | June 15, 2020

Read More 'ADMP' Stories Here

ADMP Price Returns

1-mo 65.30%
3-mo 81.46%
6-mo 38.83%
1-year -12.17%
3-year -78.96%
5-year -71.06%
YTD 44.20%
2019 -68.87%
2018 -48.86%
2017 39.68%
2016 -41.67%
2015 -12.48%

Continue Researching ADMP

Here are a few links from around the web to help you further your research on Adamis Pharmaceuticals Corp's stock as an investment opportunity:

Adamis Pharmaceuticals Corp (ADMP) Stock Price | Nasdaq
Adamis Pharmaceuticals Corp (ADMP) Stock Quote, History and News - Yahoo Finance
Adamis Pharmaceuticals Corp (ADMP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7546 seconds.